Metsera, a NYC-based clinical-stage biopharmaceutical firm, raised $290M in funding.
The spherical was led by ARCH Enterprise Companions with participation from different healthcare traders together with F-Prime Capital, GV, Mubadala Capital, Newpath Companions, SoftBank Imaginative and prescient Fund 2 and different undisclosed traders.
The corporate intends to make use of the funds to develop operations and its R&D sector.
Metsera is a clinical-stage biopharmaceutical firm accelerating the subsequent technology of medicines for weight problems and metabolic ailments. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and mixture therapies with potential best-in-class profiles to deal with a number of therapeutic targets and meet the longer term wants of a quickly evolving weight reduction therapy panorama.
The portfolio of injectable and oral growth applications is sourced from the corporate’s proprietary library of over 20,000 intestine hormone peptides and peptide/antibody conjugates. Improvement applications embrace parallel methods and are targeted on a number of next-generation targets and mixtures. These embrace:
- GLP-1 portfolio: led by an injectable, fully-biased GLP-1 receptor agonist in Part 1 scientific trials with a possible class-leading period of impact
- A twin amylin/calcitonin receptor agonist (DACRA) engineered for class-leading period of impact which is being mixed with the GLP-1 receptor agonist
- A unimolecular GGG (GLP-1, GIP, Glucagon) engineered for class-leading period of impact and mixture with DACRA
- An oral peptide supply platform, together with two IND-ready candidates with potential best-in-class bioavailability and a number of first-in-class oral follow-on candidates
- A spread of different early-stage applications and supply modalities
FinSMEs
18/04/2024
